KRAS G12C inhibitors thus far have only been approved for use as a monotherapy in non-small cell lung cancer and as a combination therapy in colorectal cancer, partially because of the rarity of the G12C allele and partially because of a lack of drug sensitivity in certain tumor types. Here, KRAS is linked to non-small cell lung carcinoma.